-+ 0.00%
-+ 0.00%
-+ 0.00%

SCYNEXIS Granted FDA's Qualified Infectious Disease Product, Fast Track Designations For Second-Generation Triterpenoid Antifungal Therapy SCY-247

Benzinga·01/21/2026 13:02:51
Listen to the news

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration ("FDA") has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations for its second-generation triterpenoid antifungal therapy, SCY-247.